MetLife, Inc. (MET) Earnings Call Transcript & Summary
May 7, 2026
What were the key takeaways from MetLife, Inc.'s May 7, 2026 earnings call?
In the first quarter of 2026, MetLife, Inc. reported strong financial results, with adjusted earnings of $1.6 billion or $2.42 per share, reflecting an 18% increase year-over-year. The company experienced broad-based revenue growth, with adjusted premiums, fees, and other revenues rising by 10%. Management maintained its full-year adjusted earnings guidance of $1.6 billion to $1.8 billion for the Retirement & Income Solutions segment, indicating confidence in continued performance despite market challenges.
What topics did MetLife, Inc. cover?
- Strong Revenue Growth: MetLife achieved adjusted premiums, fees, and other revenues of $1.6 billion, up 10% year-over-year, demonstrating broad-based growth across nearly all business segments. CEO Michel Khalaf stated, "This quarter's performance was balanced and repeatable."
- Adjusted Earnings Performance: The company reported adjusted earnings of $1.6 billion, or $2.42 per share, reflecting an 18% increase from the prior year. CFO John McCallion noted, "Adjusted EPS grew 23%" and highlighted strong capital management as a key driver.
- Group Benefits Segment Strength: The Group Benefits segment generated adjusted earnings of $439 million, up 19% year-over-year, driven by favorable life underwriting and volume growth. Khalaf emphasized, "Life mortality in the quarter was exceptional," contributing to strong sales growth.
- Asia Market Performance: Asia delivered adjusted earnings of $487 million, a 31% increase, with sales up 22% on a constant currency basis. Management noted, "Sales performance in the quarter was very strong" due to successful product launches in Japan and Korea.
- Capital Management Actions: MetLife returned approximately $1.1 billion to shareholders through share repurchases and dividends, reflecting strong capital flexibility. Khalaf stated, "We repurchased roughly $750 million of MetLife common shares" during the quarter.
What were MetLife, Inc.'s May 7, 2026 results?
- Adjusted Earnings: $1.6 billion
- Group Benefits Adjusted Earnings: $439 million (+19% YoY)
- Asia Adjusted Earnings: $487 million (+31% YoY)
- Direct Expense Ratio: 11.9%
- Total Shareholder Returns: $1.1 billion
- MetLife Investment Management Adjusted Earnings: $47 million (+68% YoY)
MetLife's strong first quarter results reinforce its investment thesis, showcasing robust revenue growth and disciplined capital management. Investors should monitor the company's ability to sustain growth in key segments, particularly in light of regulatory challenges and market conditions. The ongoing integration of PineBridge and the successful execution of the New Frontier strategy are critical catalysts to watch moving forward.
Earnings Call Speaker Segments
Thanks, operator, and good morning to all of you. We're glad you could join us for MetLife's First Quarter 2026 Earnings Call. Prior to getting started, I want to direct your attention to the details regarding non-GAAP measures that can be found on the Investor Relations section of metlife.com, in our earnings release, and in our quarterly financial supplements, all of which you ought to look over. Joining us on the call this morning are Michel Khalaf, President and Chief Executive Officer, along with John McCallion, Chief Financial Officer and Head of MetLife Investment Management. Other members of senior management are also on hand to take part in the discussion. Yesterday evening, we posted an earnings call presentation that covers the quarter. You can find it on our website. John McCallion will walk through that presentation during his prepared remarks. Included in an appendix to the deck are disclosures, GAAP reconciliations, and additional information that you should review as well. Following the prepared remarks, we'll hold a Q&A session, and it will conclude promptly at the top of the hour. Just a reminder, please keep to 1 question and 1 follow-up. I'll now turn things over to Michel.
Thanks, John, and good morning, everybody. We had a great quarter and a solid beginning to the year, showing off the complete earnings capability of MetLife under the direction of our New Frontier strategy. Adjusted earnings surpassed the prior year across every operating business segment, with top line growth everywhere. Margins held up well, and we put capital to work prudently, investing sensibly in expansion while giving back extra capital to shareholders. Crucially, the performance this quarter was both balanced and something we can repeat. All the essential components that propel our strategy — diversified businesses, disciplined capital allocation, plus the strength of our investment portfolio and balance sheet — converged to showcase the potential and durability of MetLife's outstanding value proposition. The first year of New Frontier focused on constructing the proper engine to fuel growth and make MetLife a top-quality compounder over the long run. The second year is all about speeding up and pushing execution throughout our portfolio of market-leading businesses, through which we serve over 100 million customers. This initial quarter offers early proof that we're advancing with urgency and discipline and are positioned well to meet the ambitious financial commitments we've set. Now to the first quarter results; we posted adjusted earnings of $1.6 billion, or $2.42 per share. Adjusted earnings rose 18% compared to the same period a year ago. Adjusted earnings per share climbed 23% year-over-year, outpacing earnings growth, which mirrors our consistent capital management. Adjusted premiums, fees and other revenues, excluding pension risk transfers, grew 10% year-over-year. The growth was widespread, touching almost every business and region. Variable investment income came to $518 million pretax, which was the third quarter in a row of VII exceeding expectations. The first quarter figure landed close to the upper end of the range we shared last month, fueled by greater private equity returns of approximately 2.9%, helped along by robust venture capital results. Adjusted return on equity reached 17%, at the high end of our 15% to 17% target range and significantly above our cost of capital. Our direct expense ratio came in at 11.9%, better than last year and favorable compared with our full year target. That outcome looks even stronger once you factor in the integration of PineBridge, a business whose expense profile is structurally higher, as is typical for asset managers. Now to how our business segments performed. Beginning with Group Benefits, this segment produced adjusted earnings of $439 million, a 19% increase year-over-year. Life mortality during the quarter was outstanding, since mortality among the working population keeps improving and got an extra boost from a mild flu season this year. Total sales rose 15% in the quarter, and adjusted PFOs, excluding participating contracts, were up 4%. In national accounts, our persistency sits in the high 90s, and average customer tenure exceeds 20 years, which demonstrates how strongly Group Benefits adds to our recurring revenue model and its steady compounding of value over time. Looking forward, our market leadership, scale and lasting customer relationships leave us well positioned to generate growth in the most appealing part of the U.S. life insurance market. Employers keep recognizing that benefits going past medical coverage are a smart, budget-friendly means of helping their staff along their health and financial security paths during a strained economy. Switching over to Retirement & Income Solutions, known as RIS; adjusted earnings came in at $451 million, which is 11% higher than the prior year, driven by robust variable investment income. Following a record-breaking fourth quarter for pension risk transfers and longevity reinsurance, the more recent entrants to the portfolio, U.K.-funded reinsurance and retail annuity reinsurance, added $1.5 billion in new sales, which further underscores how varied our product lineup has become. The scope of our worldwide retirement opportunity is considerable and stretches across the globe to encompass leading markets like the United States, the United Kingdom and Japan. In those markets, demographics are fueling demand for income, and our range of products is ideally built to deliver that. Now turning to Asia. The region posted a superb quarter. Adjusted earnings reached $487 million, climbing 31%. Sales results during the quarter were extremely robust, with the region gaining 22% on a constant currency basis; in Japan, our biggest market in Asia, we observed sustained momentum in both FX and yen-denominated offerings. We additionally gained from a fresh corporate accident and health product rolled out during the quarter. All told, Japan sales climbed 26% on a constant currency basis. As for Korea, our second biggest market in Asia, a healthy economy combined with our product innovation has fueled growth, with constant currency sales climbing 44%. In Latin America, adjusted earnings came to $229 million, up 5% even with the effect of Mexico's tax change from last year. Results were buoyed by powerful sales growth and persistency during the quarter, with sales rising 20% and adjusted PFOs climbing 11%, both measured on a constant currency basis. The region showed solid underlying momentum during the quarter, spearheaded by employee benefits growth in Mexico, retirement annuity demand in Chile and the continuing rollout of Accelerator in Brazil. Now on to EMEA. Adjusted earnings hit $110 million, rising 33%, while adjusted PFOs grew 15% on a constant currency basis. Our strategic emphasis on capital-light, accident and health and life products is paying off. The accumulated effect of robust sales across numerous markets over the past several years is plainly evident in adjusted PFO and adjusted earnings growth. Before I continue, we arrived at the tough choice to divest our business in Ukraine, an extraordinary illustration of resilience amid the most difficult circumstances. Looking ahead, this market-leading franchise will be positioned even more strongly to carry on its growth trajectory under its new regional parent. Now moving to MetLife Investment Management, or MIM. The new segment posted adjusted earnings of $47 million, a rise of 68% after the first fully integrated quarter following the PineBridge acquisition. Institutional client assets under management fell 1.9% sequentially during the quarter, largely because of market depreciation in equity and public fixed income along with modest net third-party outflows. The pipeline at MIM, along with forward commitments, appears robust—especially in private assets. Let me take a moment to address artificial intelligence, which remains a key factor in pushing forward our new frontier strategy, bolstering the way the business is operated, and fueling both expansion and efficiency gains. Across the last 5 years, over $3.2 billion has been put to work in order to streamline and upgrade our technology ecosystem. Tangible, at scale advantages for customers, associates, and operations are now coming from that spending. While adopting AI in a responsible manner, we are sharpening decision-making, elevating customer service, and cutting friction throughout the enterprise. Embedding AI within core operations, paired with steady execution, is lowering complexity and expenses while boosting productivity and underpinning growth—something visible in the ongoing enhancement of our direct expense ratio. On the customer side, AI enables quicker responses, more pertinent advice, and products that are simpler to grasp, which lifts adoption. Most importantly, governance and risk oversight are woven into our AI deployment approach, which matters greatly given the confidence our customers have in us. Turning to cash and capital, we have been busy across several capital management areas.
To start, we bought back about $750 million worth of MetLife common stock and distributed roughly $370 million in common dividends, which added up to approximately $1.1 billion given back to shareholders during the quarter. In April, we purchased close to an additional $200 million of net common shares, and under our current authorization, $1.1 billion is still available. Next, as a sign of our financial strength and flexibility, a 4.4% raise in MetLife's common dividend per share was announced by our Board of Directors; and lastly, we took advantage of an opportunity during the quarter to issue $1 billion in subordinated debt, aimed at supporting our balance sheet and supplying growth capital. At its peak, demand for the offering exceeded supply by over 5 times, and it was priced at tight relative spreads, which speaks to the value and confidence the fixed income market places in MetLife's balance sheet. It's worth noting that we carried out these capital actions even while financing the quarter's considerable organic business growth, and we ended the quarter holding $3.9 billion in cash at our holding companies, sitting at the upper bound of our $3 billion to $4 billion liquidity target buffer. Before wrapping up, I want to briefly welcome Dan Glaser and Michelle Seitz, both of whom came onto MetLife's Board of Directors in February. I have every confidence that Dan's extensive background in the insurance sector and Michelle's proven history in investment management will benefit MetLife's shareholders greatly. To conclude, this quarter was outstanding and demonstrates the investment case for MetLife. Through New Frontier, the choices we make and the steps we take keep converting into sustainable earnings power, capital flexibility and appealing risk-adjusted returns throughout cycles. Our New Frontier strategy is heavily shaped by the conditions surrounding us. From shifting demographics and rising interest rates, to the blending of insurance and asset management and the swift spread of AI, we are putting MetLife in position to gain from these forces in a thoughtful, commercially disciplined manner. We are happy with how quickly the year has started; the performance this quarter bolsters our assurance in the guidance we have provided and reaffirms our conviction that New Frontier is the correct strategy at the correct moment. With that, I'll hand things over to John to go through the results in greater detail.
Thanks, Michel, and good morning to all of you. As Michel said, what this quarter shows isn't only solid headline numbers — it also shows that the quality of our earnings keeps holding up, thanks to robust growth, careful underwriting, keeping expenses in check, and sensible capital management. So I'll take you through the results for the first quarter, which will include updates on our investment portfolio, and I'll be using the Q1 earnings call presentation; we'll begin on Page 3. MetLife has gotten off to a really solid start this year, helped by the strength of our diversified, market-leading businesses, sensible capital management, and a mindset that keeps efficiency front and center. During the first quarter, adjusted EPS was up 23%, and adjusted ROE came in at 17%, which is the top end of the 15% to 17% target range we've set. Our direct expense ratio came in at 11.9%, which is better than our 12.1% annual target for 2026. Net income came to $1.1 billion, or $1.74 per share, and adjusted earnings for the quarter were $1.6 billion, or $2.42 per share. What mainly drove the gap between net income and adjusted earnings was net investment losses, mostly coming from normal trading activity in the fixed maturity portfolio. During this quarter, we saw a larger amount of trading losses because we did a more substantial amount of portfolio rotations; on top of that, this line included a modest loss tied to selling a portion of our private equity limited partnership interest. Since we've been seeing signs that the private equity secondary markets are improving, we took the opportunity to divest roughly $750 million of private equity assets at the close of Q1 at a modest discount. The structure of that transaction, just like earlier secondary sales we've done, will let MetLife Investment Management keep managing the assets that were sold. While that's a sensible way to handle our investment allocation, it also helps growth in our third-party asset management business. Let's turn to Page 4. We show adjusted earnings for every segment along with Corporate and Other, and the total rose 18% year-over-year, or 15% in constant currency, to $1.6 billion, fueled by higher variable investment income, strong volume growth, and favorable underwriting margins, partly offset by lower recurring interest margins. Adjusted earnings per share came in at $2.42, which is up 23%, or 20% on a constant currency basis, with strong earnings growth backed by sensible capital management. Now on to the businesses. Group Benefits adjusted earnings were $439 million, up 19% year-over-year, mostly driven by favorable life underwriting and volume growth. The Group Life mortality ratio for the quarter was 80.1%, which is better than our 2026 target range of 83% to 88%, reflecting mortality trends that continue to be favorable among the working age population. Our nonmedical health interest adjusted benefit ratio was 75.8%, which came in above our annual target range of 70% to 75%, consistent with seasonally higher expectations for Dental. Within disability, higher average severity also weighed on the quarter, along with higher incidence from paid family leave. Group Benefits posted strong sales in the quarter, up 15%, mainly driven by growth across both core and voluntary products. On an adjusted basis, PFOs rose 2%. That came from roughly 4% growth in the underlying business, though it was partly held back by a 2-point drag from participating contracts, which don't move earnings much. At RIS, adjusted earnings reached $451 million, an increase of 11% compared with a year earlier, mainly on the back of stronger variable investment income and better underwriting margins. In our annuity operations, mortality came in below the level seen in Q1 of '25; even so, underwriting margins stayed high because of a sizable reserve release tied to a structured settlement contract during the quarter. Even with RIS posting such a solid Q1, our expectation for the full year remains adjusted earnings somewhere between $1.6 billion to $1.8 billion, the same figure we gave on the outlook call. Investment spread across the total portfolio came to 119 basis points, sitting at the upper bound of the 100 to 120 basis points range we guided to. Core spread ex VII landed right where we expected, at 95 basis points, a sequential decline of 4 basis points, as we kept redeploying those sizable Q4 inflows, largely from PRT mandates. RIS keeps drawing strength from its origination platform. Top line metrics may have been obscured by a difficult comparison with last year's same quarter, when PRT inflows totaled $1.8 billion, but RIS adjusted PFOs, once PRTs are excluded, climbed 58%, powered by robust expansion in U.K. longevity reinsurance, post-retirement benefits and structured settlements. Over in Asia, adjusted earnings came to $487 million, a gain of 31%. The main forces behind that were greater variable investment income and substantial volume growth. Asia's most important top line growth measures carried their strong momentum into Q1. General account assets under management at amortized costs rose 7% on a constant currency basis. One major contributor was Asia sales, which grew 22% on a constant currency basis, led mostly by Japan and Korea, evidence of the traction we're getting from new product launches in both of those markets, all while keeping pricing and underwriting discipline intact the whole way through. Latin America's adjusted earnings were $229 million, 5% higher than a year earlier. Measured on a constant currency basis, though, adjusted earnings fell 9%, as the Mexico VAT change and less favorable taxes relative to last year's same quarter outweighed solid volume growth throughout the region along with favorable underwriting. Latin America turned in strong top line growth, with adjusted PFOs rising 25%, or 11% on a constant currency basis. Sales there grew 20% on a constant currency basis, lifted by strong gains in Brazil, Mexico and Chile — a plain sign of durable demand and ongoing execution throughout this franchise. EMEA adjusted earnings were $110 million, up 33%, and up 28% on a constant currency basis, driven largely by vigorous volume growth. Adjusted PFOs there rose 19%, or 15% on a constant currency basis, while sales increased 17% on a constant currency basis, with growth spread broadly across the region. The robust top line expansion of recent years is now converting into earnings power that is stronger and more consistent. Now to MetLife Investment Management, or MIM. Adjusted earnings there were $47 million in the first quarter, higher than the $28 million posted a year ago and consistent with the outlook we shared in February. The main factors behind this were expansion in our business, which includes buying PineBridge, along with beneficial expense margins. Since the first quarter carries seasonally elevated costs, we anticipate adjusted earnings will strengthen over the course of the year, helped by ongoing work to integrate PineBridge. Roughly $2 billion left from institutional clients in the quarter, which mirrors heightened market swings and the effect of merging the 2 platforms. That said, outflows leveled off during the later portion of Q1 and through April up to now, and a strong pipeline lies in front of us. Corporate and Other posted an adjusted loss of $177 million for the first quarter, versus a loss of $129 million during the same period last year. The shift from the prior year came from earnings given up due to last year's strategic reinsurance transactions, reduced recurring interest margins, and less beneficial expense margins. Higher variable investment income partly made up for this. And our effective tax rate on adjusted earnings for the quarter came in at 24%, the lowest point of our 2026 guidance range of 24% to 26%. Let's turn now to Page 5. This chart shows pretax variable investment income across the 4 quarters of 2025 plus the first quarter of 2026, which totaled $518 million.
During the first quarter, the reason our quarterly run rate came in above what was implied stems from private equities, which delivered an average return of 2.9%, whereas real estate and other funds posted an average return of 0.8%. Just to remind everyone, PE along with real estate and other funds get reported on a one quarter lag, and they're accounted for using a mark-to-market basis. Turning to Page 6, we show VII post-tax broken out by segment along with Corporate and Other across the 4 quarters of 2025 plus Q1 of '26. The bulk of VII assets sit in Asia, RIS and Corporate and Other, which fits with the long-term nature of these obligations. By the end of March in 2026 — specifically the 31st — our VII assets had grown to a cumulative $18.2 billion. Of that figure, Asia accounted for just under 50%, while RIS contributed around 30%, and Corporate and Other made up the remaining 20% or so. Our practice is to run operations assuming VII will settle at a normalized level as time goes on, and we remain at ease with the guidance we've given for the entire year. Turning now to the private fixed income portfolio, details of which appear on Page 7. For many decades, private assets—including private fixed income—have formed a component of how we invest, and we've established a demonstrated history of rigorous underwriting, solid governance and consistency with our liability profile; as of March 31, the private fixed income portfolio shown in this chart is valued at roughly $85 billion. The bulk of these holdings consists of traditional private placement and infrastructure. Much like our general account, quality is high in this portfolio, with approximately 95% rated investment grade. It is thoroughly diversified and built to hold up across market cycles. In addition, our exposure remains constrained in the areas that are getting the greatest focus in the current market. On our books, you won't find any business development companies, or BDCs. Middle market loans account for less than 1% of our general account. And private assets, when combined with our long-term illiquid liabilities, offer particularly compelling relative value. If handled with care, these holdings produce additional gains through direct origination, tighter covenants and collateral protections. Turning now to Page 8, which lays out an overview of our software and software-related investments. To tackle this space thoroughly, we've taken a broad approach. The allocation sits intentionally small inside a heavily diversified portfolio, covering both direct and indirect investments. Investment grade characterizes most of this portfolio, which is spread across issuers, structures and strategies, and ranks high in the capital structure. On our books, the direct piece sits at $2.5 billion — that's 0.6% of the general account — and it's mostly held in tech names that lead their markets, carry strong capital levels, and have plenty of liquidity. Then there's the indirect side at $6.3 billion, or 1.4% of the general account, which is spread out over funds and structures that come with credit protection and a conservative approach, so the downside is contained. Turning to private equity, software comes to $1.3 billion overall, distributed across a very diverse mix of holdings, and you'd expect returns and cash flows to differ from one investment to the next. Venture capital, meanwhile, totals $3.5 billion and leans heavily toward AI businesses, which are getting a lift from richer valuations and added favorably to this quarter's returns. Take our venture capital portfolio, for instance — it produced a 6.8% return during this quarter. To put it plainly, the software exposure we carry is deliberate, tightly monitored, and does not raise alarms from either a risk or a capital standpoint; let's now move to expenses, starting on Page 9. For the first quarter of '26, our direct expense ratio was 11.9%. That beats the 12.1% full-year goal we had established. As a point of comparison, the figure stood at 11.7% for all of 2025, and it was 12% in last year's first quarter. Strong PFO growth, combined with ongoing cost control, is what produced this quarter's outcome, letting us take in the approximately 50 basis point hit from the PineBridge acquisition that we had already told you about, and still finish ahead of our target. We continue to take a full-year view when it comes to expense management, and the results this quarter give us more confidence that we can hit our 2026 target. Now let's move to Slide 10. MetLife's capital position remains strong, and its liquidity is solid. At the holding companies, cash and liquid assets came to $3.9 billion as of March 31, which sits near the top of the $3 billion to $4 billion target cash buffer range. In the first quarter, roughly $1.1 billion went back to shareholders, and that figure included about $750 million in share repurchases. We also bought back around $200 million more in shares during April. These capital moves show confidence in near-term earnings as well as the durability of long-term free cash flow. For our U.S. companies, the 2025 combined NAIC RBC ratio reached 379%, which is well above our 360% target ratio. For the first quarter of 2026, preliminary statutory operating earnings came in at roughly $610 million, while net income was about $170 million. Our U.S. statutory adjusted capital, estimated on an NAIC basis, stood at approximately $16.2 billion as of March 31 — a 5% decline versus the end of '25. That drop was driven mainly by seasonally elevated dividends from U.S. entities paid during Q1, which were partly offset by operating earnings. Turning to Japan: once regulatory filings wrap up in June, we anticipate our initial economic solvency ratio, or ESR, will land in the middle of the 170% to 190% target range for the fiscal year ending March 2026. To wrap up, MetLife turned in a strong first quarter, demonstrating disciplined execution companywide as we begin the second year of our New Frontier strategy. We saw growth across the board on the top line, along with solid returns and careful cost control — all of which highlight how high-quality and sustainable our earnings are. At the same time, our robust capital position, liquidity, and free cash flow allow us to manage capital in a steady, disciplined way. Because our investment portfolio is high quality and well diversified — and because we've spent decades building private asset expertise and risk management capabilities — we're well positioned to navigate market cycles, and we have only limited exposure to the sectors drawing the most attention. When you put all of this together, it strengthens our belief that MetLife can keep compounding value over time and produce appealing, reliable returns for shareholders. With that said, I'll hand the call back to the operator so we can take your questions.
I'd like to begin with Group Life, if I may, and direct this to Ramy. For roughly 2 years, we've observed that the mortality trend among the working-age population has been getting better. So I'm curious whether you've carried out additional analysis regarding the causes behind that, and whether you view the pattern we've been seeing as something that can last. I don't believe we're able to pick up the response — speaking for myself, at least, I can't.
Yes, apologies. Give me a moment — just a second here. Suneet, is my voice coming through for you at this point?
Yes, I can.
All right. Apologies — there was an issue with the microphone on our end. Thanks for asking; what I'll do is offer some context on the quarter, and then explain how we view whether these results can be sustained. The quarter's results make us quite happy. Roughly 2 points of favorable development from the prior quarter came through; on top of that, we saw favorable severity of about another 0.5 point, which tends to move around from one quarter to the next. And as you mentioned, when you look at the CDC data, we're also observing favorable working age mortality overall. Now, many different things could be driving that favorability. Some of those factors include a COVID-related pull-forward effect, some have to do with GLP-1 drugs, and there are many other things we're looking into and analyzing that I won't get into right now. But when you take a step back and think about how this affects our results, keep a couple of points in mind. First, while we do operate in a competitive environment, it's also a market where we specifically can differentiate ourselves on things beyond price. So we've talked about our strategy for how we bring our value proposition to our clients, particularly those looking to achieve more with less. Disability, dental, and voluntary coverage frequently get sold alongside life insurance, and because of that bundling, we're able to evaluate profitability across the whole customer relationship and safeguard our margins overall. On the life side specifically, should the favorability we're seeing hold up and become credible on those RIS, then some share of it would likely find its way back into pricing — though that would take place step by step. So frame it as something measured in years rather than quarters when you're thinking about our underwriting ratio. Hopefully that answers it.
Yes, that helps; and maybe if we turn to Japan, it looks as though regulators there are taking a lot more actions. And I believe the secondment matter is one you're involved in. I think it's something affecting the whole industry; but I'm just wondering whether you could update us on the situation there and whether you know of any additional regulatory reviews that might affect Met's business in that country.
Suneet, this is Lyndon; so, as you put it, this matter has affected a number of companies throughout the industry. And clearly we're treating it very seriously. We've carried out a very thorough review throughout the entire company. Every seconded employee is back in their role, and we've stopped the practice. And we're taking many steps to sort of collaborate with our customers, our partners and regulators to settle the matter. And all the specifics of the review we've done, all the remedial measures we've implemented are available on our website. We're talking with the FSA about many different matters. The press release mentioned we had a reporting order, but right now all our discussions with the regulators remain confidential.
Right, and let me just build on what Suneet was saying — I want to stress this once more: this is something the whole industry is dealing with. As you could tell from the quarter, there's been zero effect on what we do, on our results, or on our sales. So like Lyndon mentioned, we're kind of — everybody, the entire industry, is in the process of sorting this out together with the regulator. And from where we sit, this isn't tied to any one particular company. It really comes down to a shift in how the industry operates.
Perhaps I'll begin by approaching the Japan topic from the other direction. Your sales there were pretty robust. Could you expand a bit on the favorable trends you're observing that produced this result? And what's your outlook for the remaining part of the year?
Sure. This is Lyndon. I'll address that. Well, it was indeed an exceptionally solid quarter; the results we achieved during those three months make us quite happy. Revenue has risen 22% compared with the same period last year. Allow me to provide some detail regarding Japan and the remainder of Asia. I'll begin with Japan. Japanese sales climbed 26% versus a year earlier, which stems largely from the power of our distribution network throughout every channel we operate; we additionally gained from highly effective introductions of new offerings during those three months; our life sales increased. That resulted from the yen variable offering together with a single premium product denominated in U.S. dollars; regarding A&H offerings, we brought a fresh product to market during the quarter, and A&H revenue actually climbed 77% compared with the prior-year period; therefore, the yen A&H lineup delivered excellent results. Turning to annuity revenue, it held firm relative to an exceptionally tough comparison from the earlier year, yet we keep observing a degree of forward movement in single premium offerings priced in U.S. dollars. A significant element this quarter was the composition of our business, split between yen and dollar offerings, which came in at roughly 50 to 50, demonstrating a highly varied product range. Now shifting to the remainder of Asia, revenue there climbed 18% versus the prior-year period. Korea served as a primary engine here. Its sales increase reached 44%. In this market as well, we noticed forward movement in our U.S. dollar revenue, since we managed to apply what we accomplished in Japan regarding U.S. dollar offerings, along with our investment know-how, and bring it over to Korea; furthermore, we observed positive results in our Korean won offering there, which stemmed chiefly from the favorable macroeconomic conditions, especially the climbing equity markets. Thus we've begun the quarter strongly; as we look forward, some slowing in the rates of year-over-year growth is reasonable to anticipate, simply because the earlier year's comparisons were so strong, yet we genuinely anticipate that the forward movement we possess will persist as we move into the second quarter.
Regarding non-medical health, might you provide additional detail about the primary factors that shaped this quarter? Plus, what's your outlook for the remaining portion of the year?
Certainly, Ryan; Ramy speaking. Considering the quarter, I'd highlight 3 drivers. The first is dental, which largely came in as we had anticipated. We saw the usual seasonal uptick in dental utilization during the quarter, and that does affect the ratio. We anticipate utilization will ease during the back half of the year, and this aligns with patterns seen historically; on the disability side, we saw an increase in claims. That stemmed from the effect of newly enacted state-mandated paid family leave programs. Such new programs exhibit a claims pattern featuring elevated initial claims that generally settle down. Thus, once more, we'd anticipate that effect will likewise ease during the back half of the year. Then there's the third element, which John mentioned during his prepared remarks — we noticed somewhat heightened severity in LTD. It's worth noting that although this was up compared with the prior year, on a sequential basis it was actually unchanged across the past 3 quarters. So we truly don't detect any indication of a trend regarding severity, and it's very consistent with the sort of quarterly swings we'd typically observe. So when you combine all these elements, from a total standpoint, returning to your question, we'd anticipate the ratio will ease, but expect that easing during the back half of the year, assuming that shows up in our results.
My first question concerned RIS spread. I believe the core spread came down somewhat on a sequential basis. Yet you've additionally added quite a bit of new business from PRT along with other products during the last couple of quarters. So could you help with how you're viewing core yield or spread? And how should that move if there's any lift from putting some of that cash to work or shifting some assets down the road?
Yeah. Appreciate the question. Wes, this is John; so like you said, RIS spreads came in at 119 basis points for the quarter, falling roughly 5 basis points overall on a sequential basis, though frankly, that sits at the high end of our 100 to 120 basis point guidance range, with VII adding around 24 basis points. So it was basically unchanged, which mirrored, clearly, our robust private equity performance; and so when you take out VII, core spreads stood at 95 basis points; and that 4 basis points of quarter-over-quarter decrease was mostly consistent with what we talked about in February. As we'd guided, there was — clearly, we saw a big amount of new flows in 4Q, mainly from the PRT mandates; that produced a bit of a headwind in Q1, while we keep rotating that portion of the — or a portion of the portfolio; and so looking forward to 2Q, we do anticipate some betterment from fewer asset rotations, but we're also working in a setting where the yield curve stays persistently flat with the short end greater than perhaps relative to our outlook assumption of the curve steepening. So that in fact places a bit of a headwind on us. I think all things considered, what we expect for Q2 is that core spreads will stay near where we are in Q1, possibly a touch higher, modest improvement in Q2. And total spreads will keep tracking toward our full year range.
Understood. And then, secondly, I believe Sun Life put out a press release the week before last about settling a class action with policyholders. In that release, I think they mentioned they could pursue recourse from MetLife for roughly CAD 200 million on a gross basis. So — I know that's a small figure, but I just wanted to check whether that's something we ought to be considering as a near-term effect on MetLife.
Wes, this is Michel. Thanks for asking. So I think you're referring to the press release Sun Life issued on April 30. The claims Sun Life has made are best described as baseless and misleading. MetLife wasn't named as a defendant in the class action suit referenced; and Sun Life hasn't taken any legal action to enforce the alleged indemnity claim against MetLife. In fact, at present there are no legal proceedings between the parties. We strongly dispute that we owe Sun Life any indemnity at all for the claims made in the underlying settlement. And the final thing I'd mention is that Sun Life, and Sun Life alone, is responsible for its own decisions and actions in this matter.
To begin with, John — regarding statutory net income, was that figure $170 million for the first quarter? If that's right, was there anything specific putting pressure on that outcome? And, thinking more widely, what's your view on capital generation as we begin the year?
Correct. Tom, yes — regarding statutory capital, as I noted during the opening remarks, we saw roughly a 4% decrease during the quarter. The main driver, as I said, is dividend seasonality affecting our U.S. entities. Our practice tends to be taking a bigger dividend during the first quarter. Meanwhile, dividends coming from entities outside the U.S. have been concentrated more heavily in the other quarters. So this has generally been our historical approach to managing capital across the year. What matters, I'd say, is that nothing has truly shifted regarding either our capital trajectory or how we generate capital. Specifically, we keep showing a free cash flow ratio between 65% and 75%, and we stay confident about achieving that through New Frontier. Lastly, during 2025, our RBC ratio came in at 379%, comfortably above the 360% threshold. So it's very consistent with how we've run things across the past several years. On the whole, we think this still demonstrates our robust capital resilience and discipline, and there's genuinely nothing worth flagging. You observed what I'd describe as a normal amount of credit losses this quarter, somewhat elevated trading losses, and simply the usual seasonal pattern of Q1. Looking back, you'll find it lines up quite closely with earlier quarters.
Understood. For my follow-up, I'd like to pose a broader strategy question regarding the investment side. What's your thinking on things? I'm aware there were some reallocations happening with PRT and similar items. But I suppose beginning with your commercial mortgage loan portfolio, I've observed significant shrinkage there. So it appears you aren't originating as much in that area, or at minimum not keeping as much there. That suggests to me you're somewhat more cautious going forward regarding the CML side. Where are you moving those allocations? And which areas make you more optimistic? Could it be private credit? Or perhaps just a bit of insight into what you're considering more generally about where you intend to direct new dollars?
Yes. Tom, that's a valid observation; and I believe as with any market conditions and how we handle it, clearly, we evaluate relative value, correct? And we — this explains why having a diversified platform matters so much, with strengths and capabilities spanning multiple asset classes, because frankly, certain asset classes may appear more difficult at various moments. Regarding your comment on real estate specifically, we keep observing a situation there, where liquidity and price discovery have been increasing, and we anticipate this pattern will persist throughout the year. And it has assisted in normalizing pricing and similar factors; and thus there are, I'd say, opportunities that are getting better, but unexpectedly, new issuance and new origination spreads remain fairly tight; so we're exercising selectivity in that regard, and we believe that's the optimal strategy for this asset class. As for your inquiry about other areas we're examining, I think we possess a range of capabilities in private assets. Asset-backed financing is likely among the areas where we're identifying opportunities for risk-adjusted returns that are quite robust; but I think across every asset class, we can locate it, though perhaps concerning broad sector themes, that's likely the area on a relative basis demonstrating superior value.
Starting with MIM and PineBridge, which is now part of the picture — could you discuss what you expect for flows, or give us additional detail on that robust pipeline you referenced during your prepared remarks? Also, could you address how much you can take advantage of the overseas distribution that this deal brings?
Joel, this is John. Let me begin by saying that what lies ahead for MetLife Investment Management has us genuinely enthusiastic. We've just completed the first quarter following the acquisition. Although we're still in the early stages, the strides we've made in integration, in engaging clients, and in building pipeline have us quite encouraged. On the integration side, our aim from the start was to move fast while staying intentional. A new MIM leadership team was announced, drawing people from both organizations. We're currently in the middle of combining core investment platforms so we can capture operating synergies. Beyond that, from day one we've concentrated on operating as a single MIM platform. And that, in a broad sense, was in fact the strategic justification for uniting these 2 companies. We've also taken the initiative with clients and consultants regarding our outreach and our vision, discussing these investment capabilities, and the response we've gotten has been uniformly favorable. We're actually noticing some excellent possibilities, with early indications of cross-selling starting to surface. So I suppose what I'd say is that, on the whole, these initial days have only kept confirming how well PineBridge fits strategically. Regarding the fresh pipeline, my take is that it's nicely varied. Some of it involves committed, new commitments. There are chances to put capital to work within our current mandates. We also have certain client activity at a late stage. So, all things considered, as you're aware, institutional asset management can by nature be uneven and come in bursts at times. Still, I believe what has us truly excited is that the engagement and momentum we're witnessing are quite positive and very constructive, and we're simply watching these — these possibilities take shape across asset classes and geographies. As you note, one appealing aspect of PineBridge joining us is that they genuinely delivered an international, non-U.S. footprint to our firm. Roughly 50% of their AUM sits outside the U.S. So we devote considerable time with the teams, sort of considering how we might, as I mentioned before, consider those cross-sell opportunities, and we're uncovering plenty of opportunities right from the start. So, taking a step back, even though integration is at an early point, and there are certain natural — I'll call them early-stage consolidating situations that arise when it comes to flows, we feel quite good about the demand that exists for our products, how deep the pipeline is that we're seeing, and our capacity to keep producing new net flows.
Understood; that was quite useful. And Ramy, perhaps you could describe what you're observing regarding competition in the different markets where you operate, within the group segment? Plus any insight into what's driving the top line, and why group ex participating policies sit near the bottom edge of your target range?
Appreciate it, Joel. Let me address the top line matter first; as we've explained previously, participating policies do have an effect on PFOs, yet they don't truly affect our earnings. So we prefer to view the genuine gauge of top line growth as one that leaves out participating policies. During this quarter, we recorded just above 4% growth on that basis; and as the market leader, still expanding at such rates, and in absolute dollar terms, we're definitely quite happy with our growth rate here; and sure, even though we operate in a competitive space, our value proposition connects with the marketplace and keeps delivering for our customers, and in turn, delivers for our shareholders. So regarding drivers, everything has really been firing on all cylinders this quarter. Our persistency has improved. That improvement was widespread, especially noticeable in our dental book; we've managed all of that persistency improvement while still hitting our expectations on rate actions throughout the business. Sales momentum is very strong, widespread across core and voluntary. And we keep advancing the strategy we outlined at Investor Day concerning re-enrollment. We discussed those twin gaps — a confusion gap and a protection gap — and how bridging them will produce better enrollment outcomes, and we're witnessing that through double-digit growth in voluntary products within our portfolio. So overall, I'd say, as the industry leader with clear competitive differentiators, we're very happy with the top line momentum here.
Let me circle back to MIM for a moment. You brought up a few outflows tied to third parties. Were those driven by PineBridge deflections, or did they originate elsewhere?
Yeah. No, my sense is it's a combination, correct? So a few things happened — we saw certain activity following the close that we'd anticipated, so to speak, during the early part of the quarter; and beyond that, we experienced the kind of allocation moves by clients that tend to show up at the beginning of a year. So both elements are in play.
Understood. And I'd really value hearing how things are going with your annuity reinsurance flow. At this moment, how many cedents do you count yourselves involved with?
Tracy, right now there are 2 partners with whom we collaborate closely on the reinsurance front. And let me just — I'd like to offer a little additional detail on that: the partners we work with value what our financial strength, investment capabilities, liquidity and capital flexibility allow us to deliver. That said, I'd add that we remain quite selective about whom we choose to partner with, since we examine the quality of the liabilities being originated, and especially, we scrutinize the cost of funding attached to those liabilities. So in our view these partnerships benefit both sides and really reflect the strategy of pursuing adjacencies that align with our strengths. And — Michel brought that up during his opening remarks regarding retail reinsurance. The other adjacency where we're experiencing considerable tailwinds is U.K. funded reinsurance. And year-to-date across those 2 areas, we've seen $2 billion of inflows, and these are operations that essentially went from nothing at Investor Day to where we stand now 18 months afterward.
To start, would you share your view regarding EMEA? Profits came in higher than the quarterly run rate that you'd previously guided to. And the business there doesn't appear to be impacted by events unfolding in the Middle East. So I'd just like to know how you expect the remainder of the year to play out in that region.
Let me just confirm, Pablo, you meant EMEA, correct?
Right, John, that's accurate. It's simply that earnings came in stronger, and operations weren't impacted by what's happening in the Middle East?
Pablo, Michel here once more; indeed, EMEA's results have us genuinely delighted; and I'd note this has been accumulating across a couple of years now, with robust sales expansion converting into PFO expansion and earnings expansion too. I believe that likewise mirrors the extremely efficient setup we maintain across EMEA, particularly within Europe. As for what's going on in the Middle East, simply to help you grasp how EMEA's earnings break down, roughly 2/3 originate from Europe, while 1/3 comes from the remainder of the region. And approximately 50% of that 1/3 is generated by Turkey and Egypt. So obviously, we've been watching developments in the region very carefully. Keeping our associates there safe and well is our foremost concern. Up to now, no impact has appeared. And EMEA's performance during the quarter, I'd say, demonstrates that. We further believe that, assuming conditions settle from this point, no impact will emerge. And should any arise, it won't prove material to EMEA as a whole and definitely won't prove material to MetLife's consolidated results either.
Also, Pablo, regarding what lies ahead, I want to note that while this quarter was clearly quite robust, I wouldn't treat it as a baseline — meaning I wouldn't assume a quarterly pace of $90 million to $100 million going forward as part of the guidance. Looking forward, we're likely moving toward the middle to upper portion of that range.
Got it. Now for my follow-up, on disability — this may be one for Ramy once more. Given what you've observed up to this point, correct? You flagged severity and paid families — would addressing those call for rate adjustments outside the usual cycle? Also, how would you describe the way you're positioning the book now compared with the prior several years, when industry results were simply extremely robust?
Sure. Regarding our broad pricing strategy in this area, roughly 50% of the book can be repriced annually when it comes to disability; that figure reflects both client-specific experience and our own outlook. From an LTD standpoint, based on a 1 quarter of severity in this quarter — and I noted it was flattish across the last 3 quarters — nothing we're seeing suggests — would justify repricing the whole book. Apart from the severity we discussed, performance aligns closely with what we expected, whether you look at incidence, closure, or recovery rates. So we're fairly comfortable with the book's current position, though we'll keep watching it and obviously respond to each customer's individual experience. As for paid family medical leave, I described the product's character. My view is that it's an expanded STD product, and I mentioned how those claims behave on the front end. Naturally, once experience becomes more credible in later quarters, we'll consider repricing moves if they're warranted. Still, the front-end pattern isn't surprising to us. That's simply how these plans operate; and once again, I'd point out that about 50% of this business can be repriced each year. So treat this as BAU when it comes to achieving our target margins and taking pricing actions.
Thank you, everybody, for joining us this morning, and have a great day.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete MetLife, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to MetLife, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.